Introduction: There is no method of permanent ablation that is universally acknowledged, making the treatment of keloid and hypertrophic scar difficult. Conventional treatments result in variable outcomes, serious consequences, and expensive hardware. The goal was to determine whether intralesional 5-fluorouracil (5-FU) was safe and effective for treating keloids. Method: It took place at the Patna Medical College Hospital, Patna between October 1, 2020 and September 30, 2021. 140 patients were involved, split into two groups. Triamcinolone acetonide (TAC) was administered intralesionally to the patients in group A, while 5-FU and TAC were given to the patients in group B. Patients were assessed at the beginning of the treatment, at the third and seventh weeks into the treatment, and then five weeks after the end of the treatment. A total of seven injections were administered at week intervals. The effectiveness, complications, and mean reduction in scar height for each patent were evaluated. Result: The study was completed by 100 patients in total. The mean scar height decrease in group B (5-FU+TAC) was 1.142±0.4716, which was noticeably better than the scar height reduction in group A (TAC alone) of 1.893±1.0750 (t=4.780, p=0.001). Group B had greater efficacy (previously defined as >51% reduction in initial scar height) than group A, which had worse efficacy (49.1%, X2=9.261, p=0.001). Recurrence was observed in 39.1% (19) of the group A patients while it was only observed in 17.4% (9) of the group B cases (P=0.011). A typical follow-up lasted 12 months. Conclusion: Problematic scars can be treated safely, easily, and effectively with 5-FU+TAC, which also has a decreased recurrence rate when given a longer follow-up.